ArticleMovement disorders : official journal of the Movement Disorder Society2023
It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
Article in Movement disorders : official journal of the Movement Disorder Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Incidental Finding of an Asymptomatic Perielectrode Cyst After Deep Brain Stimulation for Parkinson's Disease.Cureus · 2026Article
- Powering Neurology Drug Development Trials to Reduce False Negative Results.Clinical and translational science · 2026Review
- Validation of the Norwegian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.Clinical parkinsonism & related disorders · 2026Article
- The patient-centric development of an inclusive multi-arm multi-stage trial for Parkinson's disease.Brain communications · 2026Article
- Optimizing the MDS-UPDRS Part III for early-stage Parkinson's: early supportive evidence for a limb-related bradykinesia/rigidity sub-score.NPJ Parkinson's disease · 2025Article
- Deep brain stimulation surgical timing, outcomes, and prognostic factors in patients with Parkinson's disease: A Chinese retrospective multicenter cohort study.PLoS medicine · 2025Article
- Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials.Translational neurodegeneration · 2025Review
- Outcome Selection for Research Studies in Movement Disorders.Movement disorders clinical practice · 2024Article
- Microbiome-based therapeutics for Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.Journal of Parkinson's disease · 2024Article
- Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol.BMJ open · 2023Article
- Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.Movement disorders : official journal of the Movement Disorder Society · 2023Article
- Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.Movement disorders : official journal of the Movement Disorder Society · 2023Article
- Does in-vehicle automation help individuals with Parkinson's disease? A preliminary analysis.Frontiers in neurology · 2023Article
- The Effect of Genotype on Self-Reported Dysarthria and Dysphagia in Parkinson's Disease: A Parkinson's Progression Marker Initiative Study.International journal of language & communication disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOriginal clinimetric analyses by the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) developers did not confirm the validity of summing the scores of its parts. Recent studies used the summed score of Part III and other parts as efficacy outcomes.
objectiveThe aim of this study was to establish whether summing scores of MDS-UPDRS parts can be recommended.
methodsUsing 7466 full MDS-UPDRS scores, we applied two-step factor analysis as in the original article to reassess the validity analysis with the threshold criterion set at comparative fit index ≥0.9.
resultsAll comparative fit indexes of any combination including Part III were lower than 0.90.
conclusionsSumming Part III MDS-UPDRS scores with other parts is not clinimetrically sound. The MDS-UPDRS is a validated four-part scale with corresponding individual part scores and needs to be used within the limits originally presented. © 2022 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.